| Name | Title | Contact Details |
|---|
Innopsys is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath`s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis.
OpGen, Inc. is a leading innovator in rapid, accurate genomic and DNA analysis systems and services.
IMS Group is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies. The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody. XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab. One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease. XOMA`s scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes. XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets.